Skip to main content

Advertisement

Fig. 5 | BMC Cancer

Fig. 5

From: Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer

Fig. 5

Knockdown for CD44v8–10 using siRNA increases the sensitivity of T24PR cells to CDDP. a Western blot analysis of protein expressions of CD44v8–10 and xCT in T24PR cells after transfection of siRNA specific for CD44v8–10 and these signal intensities. Left panel) Western blot analysis shows that the protein expressions of CD44v8–10 and xCT were reduced in T24PR cells transfected with siRNA #1 and siRNA #2 for CD44v8–10 as compared to those in T24PR cells transfected with siRNA for a non-targeting control. Right panel) The signal intensities of the protein expression of CD44v8–10 and xCT in T24PR cells transfected with siRNA #1 and siRNA #2 for CD44v8–10 were significantly lower than those in T24PR cells transfected with siRNA for a non-targeting control (#; p < 0.001 for both protein expression). b Cell viability relative to control at various concentrations of CDDP exposure in T24PR cells transfected with siRNA specific for CD44v8–10. After exposure to 5 μM and 10 μM CDDP, the relative cell viabilities to vehicle control in T24PR cells transfected with siRNA #1 and siRNA #2 for CD44v8–10 were significantly lower than those in T24PR cells transfected with siRNA for a non-targeting control (†; p < 0.01)

Back to article page